Mustang Bio, Inc. General form of registration statement for all companies including face-amount certificate companies

Clinical Trial and Sponsored Research Agreements (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2024

Dec. 31, 2023

For the years ended December 31, 2023 and 2022, the Company recorded the following expense in research and development for licenses acquired:


	For the year ended December 31,
($ in thousands)	2023		2022
City of Hope National Medical Center
IV/ICV		—		125
HER2		—		200
CSL Behring (Calimmune)		50		40
Fortress Annual Stock Dividend		477		1,109
Total	$	527	$	1,474


	For the three months ended September 30,				For the nine months ended September 30,
($ in thousands)	2024		2023		2024		2023
City of Hope National Medical Center
CD123	$	—	$	23	$	—	$	23
IL13Rα2		66		180		457		817
CS1⁽¹⁾		—		—		—		188
PSCA⁽¹⁾		—		—		—		44
Fred Hutchinson Cancer Center - CD20		—		142		312		1,239
St. Jude Children’s Research Hospital - XSCID⁽²⁾		—		(106)		(434)		528
Leiden University Medical Center - RAG1 SCID		—		125		241		349
Mayo Clinic⁽³⁾		—		—		(275)		551
Total	$	66	$	364	$	301	$	3,739

⁽¹⁾ Licenses and associated sponsored research agreements were terminated in May 2023.

⁽²⁾ License and associated Data Transfer Agreement were terminated in April 2024.

⁽³⁾ License and associated sponsored research agreement were terminated in June 2024.